Back to results
US 8,084,040 B2Granted
Use of bacterium for manufacture of a vaccine
AssigneeIntervet International B.V.
InventorsAntonius Arnoldus Christiaan Jacobs, Daniel G. E. Goovaerts
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of live attenuated bacteria for the manufacture of a vaccine for submucosal administration.
Claims12
A method for reducing the amount of adverse reactions in a mammal at an injection site of a live attenuated bacterial vaccine, wherein:
- the method comprises administering submucosally the vaccine, whereby the amount of adverse reactions at the injection site is reduced,
- the live bacterial vaccine comprises bacteria that cause abscess formation when administered intramuscularly, and
- the reduction of the amount of adverse reactions is measured by the amount or size of abscesses at the mucosal injection site compared to an intramuscular injection site.
A method for systemic application of live attenuated bacteria to a mammal, wherein:
- the method comprises administering the live attenuated bacteria submucosally to the mammal,
- the live attenuated bacteria cause abscess and/or lesion formation in the mammal if the live attenuated bacteria are instead administered intramuscularly or intradermally to the mammal, and
- any abscess and/or lesion formation at the site of the submucosal administration is less in total size than the abscess and/or lesion formation that would occur if the bacteria are instead administered intramuscularly or intradermally to the mammal.
Dependencies are inferred from the claim text.